Objective To assess the diagnostic value of vimentin and SFRP2 methylation for colorectal cancer screening. Methods Ninety-five qualified stool samples from different subjects consisting of 40 col-orectal cancer patients, 25 advanced adenoma patients and 30 normal controls were collected. The methylation status of vimentin and SFRP2 in stool samples was detected by methylation-specific PCR (MSP). Results The detection rates of vimentin in colorectal cancers, advanced adenomas and healthy controls were 55.0%(22/40), 48.0%(12/25), and 6.7%(2/30);the detection rates of SFRP2 were 70.0%(28/40),64.0%(16/25) and 0 (0/30);and the detection rates of FOBT were 37.5%(15/40), 12.0%(3/25) and 3.3%(1/30), respectively. The diagnostic sensitivity with combination of the two markers was 83.1%(54/65) in patients, significantly higher than that of vimentin( 52.3%, 34/65), SFRP2( 67.7%, 44/65), and FOBT examination (27.7%, 18/65)(all P<0.05), while no significant difference was found between the diagnostic specificity with combination of the two markers 93.3%(28/30) and that of vimentin 93.3%(28/30), SFRP2 100%(30/30) and FOBT examination 96.7%(29/30) (all P < 0.05). Conclusions The combination of detecting vimentin and SFRP2 methylation has great performance for colorectal cancer screening.%目的：评价在粪便样本中联合检测vimentin和SFRP2甲基化来筛查大肠癌的性能。方法搜集合格的新鲜粪便标本95例，其中40例大肠癌患者、25例进展期腺瘤患者和30例结肠镜阴性的正常人，应用甲基化特异性PCR（MSP）法检测vimentin和SFRP2甲基化状态，并与单个基因甲基化检测和粪隐血试验（FOBT）的诊断性能相比较是否有统计学差异。结果大肠癌组中vimentin和SFRP2甲基化阳性检出率分别为55.0%（22/40）和70.0%（28/40）；进展期腺瘤组中为48.0%（12/25）和64.0%（16/25）；正常对照组中为6.7%（2/30）和0（0/30）。在病例组中两基因联合检测的敏感性为83.1%（54/65），明显高于vimentin的52.3%（34/65）和SFRP2的67.7%（44/65），更要高于FOBT的27.7%（18/65）（均P<0.05）。而在正常对照组中两基因联合检测的特异性为93.3%（28/30），与vimentin的93.3%（28/30）和SFRP2的100%（30/30）以及FOBT的96.7%（29/30）相比均无明显差异（均P>0.05）。结论在大肠癌筛查中，联合检测粪便中vimentin和SFRP2基因甲基化状态明显优于单个基因和粪便潜血试验，具有潜在的应用价值。(all P<0.05). Conclusions The combination of detecting vimentin and SFRP2 methylation has great perfor-mance for colorectal cancer screening.
展开▼
